等待开盘 04-02 09:30:00 美东时间
+0.140
+3.34%
今日重点评级关注:韦德布什:维持Black Diamond Therapeutic"跑赢大市"评级,目标价从13美元升至14美元;花旗:维持Olema Pharmaceuticals"买入"评级,目标价从60美元升至62美元
03-18 10:48
Wedbush analyst Dan Ives maintains Telos (NASDAQ:TLS) with a Outperform and lowers the price target from $10 to $8.
03-17 20:38
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Telos业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **第四季度2025年业绩:** - 营收:4,680万美元,同比增长77%,超出指导区间上限(4,400万-4,630万美元) - 毛利率(GAAP):35%;调整后毛利率:36%;现金毛利率:41.9% - 调整后EBITDA:730万美元,EBITDA利润率15.6%,超出指导区间(400万-570万美元) - 经营现金流:800万美元 - 自由现金流:630万美元,自由现金流利润率13.4% **2025年全年业绩:** - 营收:16,480万美元,同比增长52% -
03-17 12:24
Telos shares are trading higher after the company reported better-than-expected...
03-16 21:19
BRIEF-Telos Corp - Q1 2026 Revenue Guidance $44.0 Million-$45.0 Million March 16 (Reuters) - Telos Corp TLS.O : TELOS CORP - Q1 2026 REVENUE GUIDANCE $44.0 MILLION-$45.0 MILLION TELOS CORP - Q1 2026 ADJUSTED EBITDA GUIDANCE $4.5 MILLION-$5.0 MILLION Source text: [] Further company coverage: TLS.O ((
03-16 21:07
Telos (NASDAQ:TLS) sees FY2026 sales of $187.000 million-$200.000 million vs $195.300 million analyst estimate.
03-16 21:04
Telos (NASDAQ:TLS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 172.73 percent. This is a 250 percent increase over losses of $(0.04) per share from the same period
03-16 21:02
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
• Intel's Q1 2026 guidance projected revenue decrease below estimates. • Increased competition and analyst sentiment shift impacted Intel's position. • Broader market downturn and geopolitical tensions contributed to negative sentiment.
03-03 19:15
Gainers Kingsoft Cloud Holdings (NASDAQ:KC) shares moved upwards by 15.1% to $...
01-12 20:06